This trial is active, not recruiting.

Condition aortic valve stenosis
Treatment medtronic engager transcatheter aortic valve implantation system
Phase phase 2
Sponsor Medtronic Bakken Research Center
Start date August 2011
End date January 2013
Trial size 150 participants
Trial identifier NCT01348438, ENG CIP-001


The purpose of the study is to evaluate the safety and clinical performance of the Engager Transcatheter Aortic Valve Implantation System in patients with severe aortic valve stenosis who are at high risk for surgical valve replacement.

United States No locations recruiting
Other Countries No locations recruiting

Study Design

Endpoint classification safety/efficacy study
Intervention model single group assignment
Masking open label
Primary purpose treatment
medtronic engager transcatheter aortic valve implantation system
Transapical implantation of the Medtronic Engager Transcatheter Aortic Valve Implantation System

Primary Outcomes

All-cause mortality
time frame: 30 Days

Secondary Outcomes

Major Adverse Cardiovascular and Cerebrovascular Events (MACCE) free survival at 30 days and 6 months post implantation
time frame: 6 months
Device and procedure related Major Adverse Events
time frame: 30 days

Eligibility Criteria

Male or female participants at least 18 years old.

Inclusion Criteria: 1. Severe aortic stenosis defined as one or more of the following by Doppler echocardiography: mean gradient > 40 mmHg; max velocity > 4m/s; aortic valve area ≤ 0.8 cm2. 2. Symptoms related to aortic valve disease, and NYHA Functional Class II or greater. 3. Logistic EuroSCORE predicted risk for mortality of ≥20%, or comorbidity judged by the investigator to pose an absolute or relative contraindication for conventional aortic valve replacement. 4. Patient is indicated for aortic valve implantation with a biological prosthesis (tissue valve) in accordance with the 2007 European Society of Cardiology (ESC) Guidelines for management of valvular heart disease. 5. Age ≥ 18 years. 6. Echocardiographically determined aortic annulus diameter of ≥19 mm and ≤ 26 mm in a long-axis view. Exclusion Criteria: 1. Congenital unicuspid or bicuspid aortic valve. 2. Severe eccentricity of calcification, defined as calcium deposits larger than 6mm in diameter. 3. Echocardiographic evidence of intracardiac mass, thrombus, or vegetation. 4. Left ventricular ejection fraction < 25%, as determined by contrast ventriculography, or echocardiography or radionuclide angiography if contrast ventriculography not available 5. Hypertrophic obstructive cardiomyopathy. 6. Patients with life expectancy less than 12 months due to an underlying non-cardiac comorbid disease. 7. Known hypersensitivity or contraindication that cannot be adequately controlled with pre-medication to any study medication or material, such as contrast medium or Nitinol. 8. Sepsis or acute endocarditis. 9. Blood dyscrasia such as acute anemia, leucopenia, or thrombocytopenia; bleeding diathesis, or coagulopathy. 10. Renal insufficiency assessed by creatinine > 2.5 mg/dl and/or end stage renal disease requiring chronic dialysis. 11. Active peptic ulcer or GI bleeding within 3 months from the planned index procedure. 12. Untreated clinically significant coronary artery disease requiring revascularization. 13. Cardiogenic shock, suspected cardiogenic shock, or hemodynamic instability requiring inotropic support or mechanical heart assistance. 14. Significant aortic disease, including abdominal and thoracic aortic aneurysm, defined as maximal luminal diameter of 5 cm or greater. 15. Need for emergency surgery, cardiac or non-cardiac. 16. History of myocardial infarction in the last 6 weeks. 17. History of TIA or CVA in the last 6 months. 18. Therapeutic invasive cardiac procedure, with the exception of aortic balloon valvuloplasty, performed within 30 days of the planned date of valve implantation, or 6 months in the case of drug-eluting stents. 19. Pre-existing prosthetic heart valve or prosthetic ring in any position. 20. Mitral regurgitation greater than 2+ by angiography or moderate by echocardiography. 21. Patient refuses a blood transfusion. 22. Patient is currently enrolled in another investigational device or drug trial that may influence the outcome of this trial.

Additional Information

Official title Transapical Implantation of the Medtronic Engager Transcatheter Aortic Valve Implantation System - The Engager European Pivotal Trial
Principal investigator Volkmar Falk, Prof.
Trial information was received from ClinicalTrials.gov and was last updated in April 2016.
Information provided to ClinicalTrials.gov by Medtronic Cardiovascular.